- Home
- TEAF vs ACHV Comparison
TEAF vs ACHV Comparison
Compare TEAF & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- ACHV
- Stock Information
- Founded
- TEAF 2017
- ACHV N/A
- Country
- TEAF United States
- ACHV Canada
- Employees
- TEAF N/A
- ACHV N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TEAF Finance
- ACHV Health Care
- Exchange
- TEAF Nasdaq
- ACHV Nasdaq
- Market Cap
- TEAF 174.8M
- ACHV 149.6M
- IPO Year
- TEAF N/A
- ACHV N/A
- Fundamental
- Price
- TEAF $11.99
- ACHV $4.10
- Analyst Decision
- TEAF
- ACHV Strong Buy
- Analyst Count
- TEAF 0
- ACHV 5
- Target Price
- TEAF N/A
- ACHV $14.80
- AVG Volume (30 Days)
- TEAF 56.1K
- ACHV 113.3K
- Earning Date
- TEAF 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- TEAF 9.20%
- ACHV N/A
- EPS Growth
- TEAF N/A
- ACHV N/A
- EPS
- TEAF N/A
- ACHV N/A
- Revenue
- TEAF N/A
- ACHV N/A
- Revenue This Year
- TEAF N/A
- ACHV N/A
- Revenue Next Year
- TEAF N/A
- ACHV N/A
- P/E Ratio
- TEAF N/A
- ACHV N/A
- Revenue Growth
- TEAF N/A
- ACHV N/A
- 52 Week Low
- TEAF $11.11
- ACHV $3.20
- 52 Week High
- TEAF $13.30
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- TEAF 21.36
- ACHV 38.91
- Support Level
- TEAF $12.61
- ACHV $4.02
- Resistance Level
- TEAF $12.68
- ACHV $4.66
- Average True Range (ATR)
- TEAF 0.10
- ACHV 0.17
- MACD
- TEAF -0.05
- ACHV -0.02
- Stochastic Oscillator
- TEAF 4.25
- ACHV 23.44
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.